Innocens Raises €1.5M Pre-Seed

Innocens, based in Antwerp, Belgium, is a health tech startup developing AI-powered digital assistants to monitor premature babies and predict life-threatening infections. The company has successfully raised €1.5 million in a funding round to support the clinical validation and commercial expansion of its diagnostic software.

Investors

This round included participation from BAN Flanders, BeAngels, NXT, the Limburg investment company LRM, and the interuniversity fund Qbic, along with existing shareholders.

Innocens Use of Funds

Innocens will use the funding to complete a new clinical validation study, pursue CE certification, strengthen its team with key expertise, and accelerate the commercial rollout of its technology across Europe.

About Innocens

Founded in 2021 by neonatologist Dr. David Van Laere, Innocens is a spin-off of the University of Antwerp and Antwerp University Hospital (UZA). The company develops an AI-powered digital assistant that continuously analyzes patient monitoring data to identify subtle changes that may indicate deterioration or sepsis in premature babies, helping clinicians assess risks earlier and make faster decisions.

Funding Details

Company Website: https://innocens.be

Company: Innocens
Raised: €1.5M
Round: Seed
Funding Date: November 27, 2025
Additional Investors: BAN Flanders, BeAngels, NXT, LRM, Qbic
Software Category: Healthcare Software
Source: https://www.qbic.be/nieuws/qbic-iii-provides-pre-seed-funding-to-innocens